Would You Take an Anti-Aging Drug Designed by AI?
A real AI drug lab is now building the future of longevity. In Abu Dhabi. With $76 million.
This isn’t a prediction. It just happened.
Juvenescence, a biotech focused on slowing aging, just raised $76M in fresh funding. Leading the round is M42, a massive healthcare group from Abu Dhabi with hospitals, genome projects, and a bio-bank covering 26 countries.
And right after the cash drop…
They acquired Ro5, a serious AI drug discovery firm.
🧠 These are the same people who helped develop SkyClaris, a drug that led to a $7.2B acquisition by Biogen. That’s FDA approval.
📍 Abu Dhabi is going all in on longevity
Together, Juvenescence and M42 are building a global AI drug development hub.
The mission?
👉 Discover new compounds faster
👉 Run smarter clinical trials
👉 Target the root causes of aging
M42 brings the real-world assets:
🏥 Clinics like Cleveland Clinic Abu Dhabi
🧬 Access to Emirati Genome Project data
📊 Health records from millions of patients
Juvenescence brings:
🧪 A pipeline of anti-aging drug candidates
🧑🔬 A scientific team ready to scale
🤖 The Ro5 platform, now fully onboard
🤖 How Ro5 actually works
Ro5 doesn’t guess. It analyzes.
Its platform links over 400 million biological relationships: genes, proteins, diseases, and pathways. It finds patterns that most humans would miss.
What it can do:
🔍 Identify high-potential drug targets
💊 Design molecules in silico (inside the computer)
🧪 Optimize them before any human trial starts
In other words, Ro5 doesn’t replace scientists. It supercharges them.
And now, Juvenescence owns the whole engine.
🧬 What are they trying to fix?
This isn’t about immortality. It’s about better aging.
The Juvenescence pipeline targets:
🧠 Cognitive decline
❤️ Cardio-metabolic dysfunction
🛡️ Immune dysregulation
🔧 Cellular damage and repair
With Ro5’s help, they’re trying to bring real solutions to the table. Not in 20 years, but in clinical trials now.
🧪 Is AI really ready for this?
Let’s look at the facts:
✅ Ro5 helped develop a drug that reached FDA approval
✅ AI platforms like AlphaFold already revolutionized protein structure prediction
✅ AI is now used to simulate trials, model toxicity, and personalize treatment pathways
So yes. AI-designed compounds are no longer a theory.
They’re already in human testing.
The next wave will go further: full discovery, trial optimization, and global deployment.
And this partnership in Abu Dhabi is at the front of it.
💭 Would you take it?
A drug built by machine learning.
Tested with AI-matched participants.
Made to reverse biological aging.
Would you take it?
You might have to decide sooner than you think.
🔍 Why it matters for all of us
This deal shows what’s really happening in longevity science:
🏛️ Governments are backing serious anti-aging innovation
💸 Investors are putting real money into healthspan, not just lifespan
🤖 AI is becoming a core tool, not a sideshow
It’s not about miracle pills or living forever.
It’s about building smarter tools to fix what breaks as we age.
We don’t need magic. We need momentum.
And this — $76M plus a powerhouse AI engine — is momentum.
